Eli Lilly and Company (NYSE: LLY), a United States-based pharmaceutical company, announced on Tuesday that it is planning to invest an additional USD450m and create around 100 new jobs to expand its manufacturing capacity at the firm's Research Triangle Park facility in North Carolina.
The expansion includes additional parenteral filling, device assembly and packaging capacity in order to support an increased demand for the company's incretin products that treat diabetes.
When the facility is completely operational in 2027, this phase of the project is likely to create around 100 new jobs, mainly manufacturing personnel, who will use advanced technology to develop incretin treatments and medical devices.
Affimed N.V. announces launch of AFM28 blood cancer trial
Cardiff Oncology doses first subject with onvansertib in Phase two ONSEMBLE trial
Kintor Pharmaceutical completes subject enrolment in phase three KX-826 clinical trial in China
FDA removes partial clinical hold on Blueprint Medicines' Phase 1/2 BLU-222 trial
CSL opens Massachusetts research and development centre
BJ Bioscience signs clinical trial collaboration and supply agreement with Merck
DermBiont Touts Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel